Skip to main content
OpenTrials

Clinical trial condition

Polymorphic Post-Transplant Lymphoproliferative Disorder

Explore clinical trials studying Polymorphic Post-Transplant Lymphoproliferative Disorder. Study availability and eligibility vary by location and protocol.

2 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Polymorphic Post-Transplant Lymphoproliferative Disorder trial results

Recruiting

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

NCT05786040

Conditions
Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder
Locations
  • Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States
  • University of North Carolina-Hillsborough Campus Hillsborough, North Carolina, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • Huntsman Cancer Institute Salt Lake City, Utah, United States
View Trial Details
Completed

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

NCT02900976

Conditions
EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder, +4 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
  • Loma Linda University Medical Center Loma Linda, California, United States
  • Children's Hospital Los Angeles Los Angeles, California, United States
View all 38 locations
View Trial Details

Related conditions